24/7 Market News Snapshot 27 March, 2025 – TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ)

March 27, 2025

DENVER, Colo., 27 March, 2025 (247marketnews.com) – (NASDAQ:RNAZ) are discussed in this article.
TransCode Therapeutics, Inc. (RNAZ) has recently demonstrated a significant upward price movement, opening at $0.576 and climbing by approximately 10.85% to a current trading price of $0.654. With a noteworthy trading volume of 5.96 million shares, there is a clear indication of heightened investor interest and momentum within the stock. This positive trend signifies a potential breakout from established resistance levels, suggesting that RNAZ could experience further gains if the current buying pressure continues. Traders are advised to closely observe moving averages and volume trends to gauge the sustainability of this bullish momentum, particularly as profit-taking strategies may come into play near key resistance areas.

In addition to the stock market activity, TransCode has made critical advancements in its clinical trial endeavors, recently achieving a milestone with the successful treatment of the first patient in Cohort 4 of its Phase I clinical trial involving TTX-MC138. This innovative therapeutic approach targets microRNA-10b, known for its role in solid tumor metastasis. To date, ten patients have undergone treatment at escalating dose levels without reported significant safety concerns or dose-limiting toxicities, showcasing the drug’s tolerability.

The progression to Cohort 4 reflects a strategic evaluation of higher dosage levels—approximately fifty percent greater than those given in prior cohorts. Currently, seven of the ten treated patients remain active participants in the trial, underscoring the candidate’s potential longevity in the treatment framework.

The study’s open-label design, coupled with ongoing safety reviews, has facilitated the Committee’s approval to enroll additional patients in Cohort 3. Sue Duggan, Senior Vice President of Operations, expressed excitement about this advancement, highlighting the robust safety and efficacy data gathered thus far. The trial’s continued progress is pivotal in establishing the safety profile and therapeutic potential of TTX-MC138, paving the way for future expansions targeting metastatic cancer types. Through these developments, TransCode reaffirms its commitment to driving innovation in RNA oncology and addressing critical challenges in cancer treatment.

Related news for (RNAZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.